Quick Answer: The Medicare GLP-1 Bridge program, launched July 1, 2026, gives eligible Medicare Part D beneficiaries access to Wegovy (semaglutide injection or tablet), Zepbound (tirzepatide KwikPen), or Foundayo (orforglipron tablet) for a flat $50 per month copayment regardless of dosage. To qualify, you must be at least 18, enrolled in Medicare Part D, and meet one of three BMI pathways: BMI of 35 or higher alone, BMI of 30 or higher with heart failure, uncontrolled hypertension, or chronic kidney disease, or BMI of 27 or higher with pre-diabetes, prior heart attack, stroke, or peripheral artery disease. The $50 copay does not count toward the standard $2,100 annual Part D out-of-pocket cap, and Medicare Extra Help (LIS) cost-sharing does not apply. The program runs through December 31, 2027.
The Medicare GLP-1 Bridge is a short-term demonstration program created under Section 402 demonstration authority that fills a coverage gap for Medicare beneficiaries who need GLP-1 weight management medications but cannot afford them at retail prices. Before July 1, 2026, standard Medicare Part D did not cover weight-loss-labeled GLP-1 drugs like Wegovy or Zepbound because federal law (the Medicare Prescription Drug, Improvement, and Modernization Act of 2003) explicitly bars Part D from covering drugs prescribed solely for weight loss. The Bridge operates as a separate channel, circumventing that statutory restriction while Congress and CMS develop a longer-term solution.
Three GLP-1 drugs are covered under the Bridge program as of July 1, 2026: all formulations of Wegovy (semaglutide, both injection and the newly-approved oral tablet), the KwikPen formulation of Zepbound (tirzepatide), and all formulations of Foundayo (orforglipron), the first once-daily oral GLP-1 approved by the FDA on April 1, 2026. Notably, Ozempic (semaglutide labeled for type 2 diabetes) and Mounjaro (tirzepatide labeled for diabetes) are not covered under the Bridge because the program targets weight-management indications specifically. Patients using those drugs for diabetes continue under their standard Part D formulary tier and prior authorization requirements. The manufacturer net price for Bridge-covered drugs is set at $245 per 30-day supply, with the $50 patient copayment and the remainder covered by the program's centralized payment mechanism.
The BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), originally intended to replace the Bridge beginning in 2027, was shelved by CMS on April 21, 2026, citing insufficient participation from Medicare Part D plan sponsors. As a result, CMS extended the GLP-1 Bridge through December 31, 2027. What happens to Bridge participants after December 31, 2027 remains unresolved. The Inflation Reduction Act selected semaglutide (Ozempic, Wegovy, Rybelsus) for Round 2 of Medicare drug price negotiation, with negotiated Maximum Fair Prices expected to take effect January 1, 2027, but that applies to the diabetes and cardiovascular indication, not weight-loss-only coverage. Patients in states participating in the Medicaid component of BALANCE (13 states as of mid-2026) retain some coverage pathway. Patients in non-participating states face potential coverage gaps after 2027.
What Medicare GLP-1 Bridge Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same medicare glp-1 bridge can cost many times more at a hospital than at your local pharmacy:
2026 Medicare GLP-1 Bridge Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Medicare GLP-1 Bridge (July 2026 - Dec 2027) | $50/month flat copay | Covers Wegovy, Zepbound KwikPen, and Foundayo. Does not count toward $2,100 Part D annual OOP cap. LIS/Extra Help does not apply. |
| Medicare Part D (standard, diabetes/CV indication only) | $0 - $200/month, capped at $2,100/year | Ozempic (diabetes) and Mounjaro (diabetes) are covered under standard Part D. Wegovy and Zepbound for weight loss are not. |
| Commercial insurance (Wegovy/Zepbound) | $25 - $300/month after prior authorization | Coverage varies widely. Many employers dropped GLP-1 weight-loss coverage in 2025-2026. Prior authorization and step therapy are standard. |
| Cash / manufacturer direct (Wegovy pill, Foundayo) | $149 - $299/month (low doses); $499/month (Wegovy injection) | NovoCare Pharmacy cash price for oral Wegovy. LillyDirect cash price for Zepbound vials: $299 - $449/month depending on dose. |
| Medicaid (weight loss indication) | $1 - $4/prescription in participating states | Medicaid BALANCE Model launched May 2026 in 13 participating states. Most state Medicaid programs require prior authorization for GLP-1 weight management. |
Bridge copay data from CMS program documentation (cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge). Retail prices reflect 2026 NovoCare, LillyDirect, and GoodRx data.
Source: CMS Medicare GLP-1 Bridge program documentation 2026, NovoCare Pharmacy, LillyDirect, GoodRx
Why Hospitals Charge So Much
Wegovy and Zepbound are self-administered outpatient medications and are rarely dispensed in a hospital setting. When they do appear on an inpatient itemized bill, the charge can far exceed retail because hospital pharmacies apply facility-rate markups that include acquisition cost, pharmacy handling, overhead, and nursing administration fees. A Wegovy pen with a manufacturer net price of $245 per 30-day supply under the Bridge can be billed at $1,500 or more in an inpatient context, representing a 500 percent markup.
Patients who receive a hospital bill listing Wegovy, Zepbound, or Foundayo at inpatient pricing should request an itemized bill and the National Drug Code (NDC) for each charge. Under the Medicare GLP-1 Bridge, the $50 copayment covers only outpatient pharmacy fills processed through the Bridge's central processor. Any hospital-billed charge for these drugs falls outside the Bridge payment mechanism and would be billed at the hospital's negotiated rate with the patient's insurance or, if uninsured, at the full chargemaster price. Always dispute inpatient drug charges that appear significantly above the manufacturer's net price.
Patient Assistance Programs
Patients who do not qualify for the Medicare GLP-1 Bridge or who need coverage before July 1, 2026 have several manufacturer programs available. Novo Nordisk (Wegovy manufacturer) and Eli Lilly (Zepbound and Foundayo manufacturer) run separate savings and patient assistance programs. Critically, the Novo Nordisk patient assistance program (PAP) does not currently cover Wegovy for weight loss. The primary cost-reduction pathways for uninsured or underinsured patients are manufacturer cash-price programs and the Medicare Bridge for Medicare enrollees. Without insurance, retail cost runs $149 to $1,349 per month depending on the drug and dose.
Patient assistance programs for Medicare GLP-1 Bridge| Manufacturer program | Cost / Benefit | How to apply |
|---|
| NovoCare Pharmacy Cash Price (Wegovy) | $199/month for new self-pay patients on low doses (0.25mg or 0.5mg); $299/month for 9mg and 25mg oral tablet doses | novocare.com |
| NovoCare Savings Card (Wegovy, commercially insured) | As low as $25/month for commercially insured patients; not available to Medicare, Medicaid, TRICARE, or VA beneficiaries | wegovy.com/savings |
| LillyDirect Zepbound Self-Pay Program | $299 - $449/month for Zepbound vials (dose-dependent); KwikPens typically higher at retail | lillydirect.com |
| Foundayo Self-Pay (GoodRx / LillyDirect) | $149/month starting price via GoodRx coupon or LillyDirect; FDA approved April 1, 2026 | goodrx.com/foundayo |
| NeedyMeds Drug Discount Card | Variable discount at most US pharmacies; works for commercially available GLP-1 products | needymeds.org |
Manufacturer savings cards (NovoCare Savings Card, any Lilly copay card) cannot be used by Medicare, Medicaid, TRICARE, or VA beneficiaries under federal anti-kickback statute (42 U.S.C. 1320a-7b). Medicare GLP-1 Bridge participants should not attempt to stack the $50 Bridge copay with any manufacturer coupon. If you have Medicare, the Bridge is your primary affordability tool for weight-loss-labeled GLP-1 drugs.
Source: Novo Nordisk NovoCare programs, Eli Lilly LillyDirect, GoodRx, NeedyMeds.org
Medicare Part D
Medicare Part D standard coverage does not include weight-loss-labeled GLP-1 drugs because federal statute bars Part D from covering drugs prescribed solely for weight loss. The Medicare GLP-1 Bridge operates as a parallel channel, separate from the standard Part D benefit and its $2,100 annual out-of-pocket cap. This distinction is critical: the $50 Bridge copay does not count toward the $2,100 annual Part D cap, and the $2,100 cap does not protect you from the $50 Bridge copay. If a Medicare beneficiary is simultaneously taking Ozempic under standard Part D (for diabetes) and Wegovy under the Bridge (for weight management), those are two separate payment flows with separate cost-sharing.
Medicare Extra Help (Low-Income Subsidy or LIS) recipients who qualify for reduced Part D cost-sharing do not receive that assistance for GLP-1 drugs filled under the Bridge. The LIS specifically applies to standard Part D claims. A low-income Medicare beneficiary enrolled in both LIS and the Bridge pays the full $50 per month for Bridge-covered drugs, even if they pay $0 or $1.50 for other Part D drugs under their Extra Help benefit. CMS has not announced any LIS-equivalent subsidy for Bridge participants as of June 2026. Beneficiaries who believe $50 per month is unaffordable should contact their State Health Insurance Assistance Program (SHIP) counselor or use the Medicare Prescription Payment Plan to spread costs across the year.
Prior authorization under the Medicare GLP-1 Bridge does not go through a patient's individual Part D plan. Instead, providers submit PA requests and prescriptions directly to a central processor managed by CMS (operated by Humana under contract). The patient's Part D plan carries no risk for Bridge-covered drugs. Patients do not need to opt in or register separately. When a prescriber submits the PA through the central processor and it is approved, the pharmacy processes the claim through the Bridge channel automatically. The patient presents at the pharmacy counter and pays $50, regardless of which covered drug was selected or at what dose.
Common Medicare GLP-1 Bridge Billing Errors
The Medicare GLP-1 Bridge introduces new billing pathways that differ from standard Part D. These billing errors have emerged during the program's first weeks:
- Pharmacy routing the claim through the patient's Part D plan instead of the Bridge central processor, resulting in a denial (Wegovy and Zepbound are not on standard Part D formularies for weight loss). Ask the pharmacist to run the claim through the Bridge adjudication channel, not your plan's BIN/PCN.
- Charging more than $50 per month or applying the Part D deductible to a Bridge-covered drug. Under the Bridge, the $50 copay is the total beneficiary obligation. The Part D deductible (up to $590 in 2026 for some plans) does not apply to Bridge fills.
- Attempting to use a manufacturer coupon (NovoCare Savings Card, LillyDirect coupon) alongside the Bridge copay. Federal anti-kickback statute bars combining manufacturer coupons with any government health insurance, including the Bridge. The pharmacy system will reject a stacked claim.
- Prior authorization submitted to the individual Part D plan instead of the Bridge central processor. The PA must go to the CMS-managed central processor to be valid for Bridge coverage. A PA approved by the Part D plan alone does not authorize Bridge pricing.
- Counting the $50 Bridge copay toward the patient's TrOOP (True Out-of-Pocket) spending for Part D. The Bridge $50 does NOT count toward TrOOP or the $2,100 annual OOP cap. If a pharmacy or plan EOB shows the Bridge copay credited toward the $2,100 cap, that is an error requiring correction.
Frequently Asked Questions
What is the Medicare GLP-1 Bridge Program and how does the $50 copay work?
The Medicare GLP-1 Bridge is a CMS demonstration program, effective July 1, 2026 through December 31, 2027, that allows eligible Medicare Part D enrollees to access Wegovy (semaglutide injection or tablet), Zepbound (tirzepatide KwikPen), or Foundayo (orforglipron tablet) for a flat $50 per month copayment. The program operates outside the standard Part D benefit, so the $50 copay does not count toward the $2,100 annual Part D out-of-pocket cap, and the Part D deductible does not apply to Bridge fills. The manufacturer net price under the Bridge is $245 per 30-day supply, with CMS funding the remainder above the $50 copay.
Who qualifies for the Medicare GLP-1 Bridge Program?
Three BMI-based eligibility pathways exist. Pathway 1: BMI of 35 or higher, no additional diagnosis required, age 18 or older. Pathway 2: BMI of 30 or higher with at least one of the following: heart failure with preserved ejection fraction, uncontrolled hypertension (systolic above 140 mm Hg or diastolic above 90 mm Hg on two antihypertensive medications), or chronic kidney disease stage 3a or above. Pathway 3: BMI of 27 or higher with at least one of: pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease. The BMI criteria are assessed at the time you first started GLP-1 therapy, not necessarily at the time you apply. You must also be enrolled in Medicare Part D.
Is there a generic or biosimilar for Wegovy, Zepbound, or Foundayo?
No. Wegovy (semaglutide for weight management), Zepbound (tirzepatide), and Foundayo (orforglipron) have no generic or biosimilar versions approved by the FDA as of 2026. Semaglutide's core patents expire approximately 2031. Tirzepatide patents extend into the early 2030s. Foundayo (orforglipron) received FDA approval April 1, 2026 and is protected by patents through at least 2040. Compounded semaglutide and tirzepatide from specialty pharmacies had limited legal availability during the FDA shortage period, but the shortage designation was lifted in 2024-2025, sharply reducing legal compounded access. Ask your prescriber about the current status.
Can I use the NovoCare Savings Card or a manufacturer coupon with the Medicare GLP-1 Bridge?
No. Federal anti-kickback statute (42 U.S.C. 1320a-7b) bars manufacturer copay cards and coupons from being combined with any government insurance benefit, including the Medicare GLP-1 Bridge. Attempting to use a NovoCare Savings Card, LillyDirect coupon, or any manufacturer coupon alongside the Bridge's $50 copay is prohibited and will be rejected at the pharmacy. If you have Medicare, the $50 Bridge copay is your total out-of-pocket obligation for covered Bridge drugs. Manufacturer cash-price programs (NovoCare Pharmacy at $149 to $499/month, LillyDirect at $299 to $449/month) are available only to patients paying fully out-of-pocket, not to Bridge participants.
What happens to Bridge participants after December 31, 2027?
CMS has not finalized a permanent replacement for the Medicare GLP-1 Bridge after its December 2027 end date. The BALANCE Model, which was intended to extend coverage through Part D plans beginning in 2027, was shelved by CMS on April 21, 2026 due to insufficient plan participation. Patients in states participating in the Medicaid component of BALANCE (13 states as of mid-2026) may have a Medicaid coverage pathway. For Medicare-only patients, the post-2027 landscape is uncertain. Monitor CMS announcements at cms.gov and contact your State Health Insurance Assistance Program (SHIP) at shiphelp.org for free guidance as the program end date approaches.
Does Medicare Extra Help or LIS apply to the GLP-1 Bridge $50 copay?
No. Medicare Extra Help, also called Low-Income Subsidy (LIS), reduces or eliminates cost-sharing for standard Part D drugs. Because the Bridge operates outside the standard Part D benefit, LIS cost-sharing subsidies do not apply to Bridge-covered drugs. A low-income beneficiary enrolled in Extra Help who also accesses Wegovy through the Bridge still pays the full $50 per month for the Bridge drug. This is a significant equity concern that CMS has not addressed as of June 2026. Low-income Bridge participants should contact their SHIP counselor to explore whether any state supplemental programs can offset the $50 copay.
How does the Bridge interact with standard Medicare Part D coverage?
The Bridge runs as a completely separate payment channel from your standard Medicare Part D plan. Your Part D plan carrier has no role in approving or processing Bridge claims. Prior authorization goes to a CMS-managed central processor (operated by Humana). The $50 Bridge copay does not count toward your plan's deductible or the $2,100 annual out-of-pocket cap. If you take a diabetes GLP-1 like Ozempic under standard Part D simultaneously with Wegovy through the Bridge, those are two separate claims with separate cost-sharing. The formulary tier and prior authorization pathway for each are entirely different.
What if my insurance denies coverage for Wegovy or Zepbound and I do not have Medicare?
Appeal the denial in writing within the time limit stated on your denial notice (typically 30-60 days). Ask your prescriber to file a peer-to-peer review and document the medical necessity with cardiovascular risk data, BMI documentation, and prior treatment history. If the commercial plan uses step therapy, request a step-therapy override using prior GLP-1 experience or contraindication evidence. If appeals fail, the manufacturer cash-price pathway remains: NovoCare Pharmacy offers Wegovy injection for $499/month and the oral Wegovy tablet starting at $149/month for self-pay patients. LillyDirect offers Zepbound vials at $299 to $449/month. Foundayo is available via GoodRx coupon at $149/month. These prices do not require income qualification. You can also check needymeds.org for additional patient assistance resources.
